RT Journal Article
SR Electronic
T1 Tocilizumab and sarilumab alone or in combination with corticosteroids for COVID-19: A systematic review and network meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.05.21259867
DO 10.1101/2021.07.05.21259867
A1 Zeraatkar, Dena
A1 Cusano, Ellen
A1 Martinez, Juan Pablo Díaz
A1 Qasim, Anila
A1 Mangala, Sophia O.
A1 Kum, Elena
A1 Bartoszko, Jessica J.
A1 Devji, Tahira
A1 Agoritsas, Thomas
A1 Lamontagne, Francois
A1 Rochwerg, Bram
A1 Vandvik, Per O
A1 Brignardello-Petersen, Romina
A1 Siemieniuk, Reed
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.05.21259867.abstract
AB Objective To compare the effects of interleukin-6 (IL-6) receptor blockers, with or without corticosteroids, on mortality in patients with COVID-19.Design Systematic review and network meta-analysisData sources WHO COVID-19 database, a comprehensive multilingual source of global covid-19 literature, and two prospective meta-analysesStudy selection Trials in which people with suspected, probable, or confirmed COVID-19 were randomized to IL-6 receptor blockers (with or without corticosteroids), corticosteroids, placebo, or standard care.Results We assessed the risk of bias of included trials using a modification of the Cochrane risk of bias tool. We performed a Bayesian fixed effect network meta-analysis and assessed the certainty of evidence using the GRADE approach.We identified 45 eligible trials (20,650 patients), 36 (19,350 patients) of which could be included in the network meta-analysis. 27 of 36 trials were rated at high risk of bias, primarily due to lack of blinding. Tocilizumab (20 more per 1000, 15 fewer to 59 more; low certainty) and sarilumab (11 more per 1000, 38 fewer to 55 more; low certainty) alone may not reduce the risk of death. Tocilizumab, in combination with corticosteroids, probably reduces the risk of death compared to corticosteroids alone (35 fewer per 1000, 52 fewer to 18 more; moderate certainty) and sarilumab, in combination with corticosteroids, may reduce the risk of death compared to corticosteroids alone (43 fewer, 73 fewer to 12 more; low certainty). Tocilizumab and sarilumab, both in combination with corticosteroids, may have similar effects (8 more per 1000, 20 fewer to 35 more; low certainty).Conclusion IL-6 receptor blockers, when added to standard care that includes corticosteroids, in patients with severe or critical COVID-19, probably reduce mortality. Tocilizumab and sarilumab may have similar effectiveness.Systematic review registration NAWhat is already known on this topic?IL-6 receptor blockers have immunosuppressive effects that may be important in COVID-19 patients with immune system dysfunction and inflammationCorticosteroids reduce the risk of death in patients with severe or critical COVID-19What this study addsOur systematic review and network meta-analysis provides a comprehensive review of the evidence addressing the effects of IL-6 receptor blockers, alone or in combination with corticosteroids, in COVID-19IL-6 receptor blockers when added to a standard care that includes corticosteroids, in patients with severe or critical COVID-19, probably reduce mortality.Tocilizumab and sarilumab in combination with corticosteroids may have similar effectiveness for reducing mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: This project is supported by two CIHR Operating Grants (VR4- 172738; MM1- 174897).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB exempt. All data secondary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript.